Blockchain Registration Transaction Record

Lantern Pharma Completes Phase 2 Trial Enrollment in Japan Ahead of Schedule

Lantern Pharma advances Phase 2 HARMONIC trial in Japan for never-smoker NSCLC, showcasing AI's role in transforming cancer therapy development.

Lantern Pharma Completes Phase 2 Trial Enrollment in Japan Ahead of Schedule

This news is significant because it highlights the progress in developing targeted cancer therapies for never-smoker NSCLC patients, a group with limited treatment options. Lantern Pharma's use of AI and machine learning to accelerate drug development could revolutionize oncology treatment, offering faster, more effective solutions to patients worldwide. The successful enrollment in Japan also demonstrates the global potential of these therapies, particularly in regions with high prevalence rates of specific cancer types.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x001556ad0db5291b916607d5e1bd31fff22d9243b0a3b807d5434e0ed5604850
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintpitapicoLw8m-1897c0a0b8ee9657b1bf964953745326